← Back to Search

HD-EEG for Nervous System Disorders

N/A
Waitlist Available
Research Sponsored by Dartmouth-Hitchcock Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Any neurologic or psychiatric diagnosis such as stroke, tumor, or psychosis judged to interfere with high-density EEG
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 - 90 minutes
Awards & highlights
No Placebo-Only Group

Summary

This trial will help researchers learn more about the brain and how it works.

Who is the study for?
This trial is for individuals who can perform specific tasks and give consent on their own. It's suitable for those with epilepsy, healthy subjects, or other nervous system disorders. People with conditions like stroke, tumors, or psychosis that could affect EEG results cannot participate.
What is being tested?
The study is testing a new method called high-density electroencephalogram (HD-EEG) to map brain functions related to movement, sensation, language, emotion, and thinking in people with neurological conditions.
What are the potential side effects?
Since HD-EEG is a non-invasive recording technique of brain activity there are typically no side effects associated with the procedure itself.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have any brain conditions like stroke or psychosis that could affect EEG tests.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 - 90 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 - 90 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Localize brain functions in patients and healthy controls
Secondary study objectives
Localize brain areas associated with lesions
Localize brain areas involved in emotion
Localize brain areas involved in language
+3 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

5Treatment groups
Experimental Treatment
Active Control
Group I: High-density EEG localization in tumor patientsExperimental Treatment1 Intervention
High-density EEG will be used for brain localization in tumor patients
Group II: High-density EEG localization in stroke patientsExperimental Treatment1 Intervention
High-density EEG will be used for brain localization in patients who have recently experienced a stroke
Group III: High-density EEG localization in peripheral nerve patientsExperimental Treatment1 Intervention
High-density EEG will be used for brain localization in patients with peripheral nerve dysfunction
Group IV: High-density EEG localization in epilepsyExperimental Treatment1 Intervention
High-density EEG will be used for brain localization in epilepsy patients
Group V: High-density EEG localization in healthy controlsActive Control1 Intervention
High-density EEG will be used for brain localization in healthy controls

Find a Location

Who is running the clinical trial?

Dartmouth-Hitchcock Medical CenterLead Sponsor
537 Previous Clinical Trials
2,539,866 Total Patients Enrolled
13 Trials studying Epilepsy
1,074 Patients Enrolled for Epilepsy

Media Library

High-density electroencephalogram (HD-EEG) Clinical Trial Eligibility Overview. Trial Name: NCT04266041 — N/A
Epilepsy Research Study Groups: High-density EEG localization in epilepsy, High-density EEG localization in healthy controls, High-density EEG localization in tumor patients, High-density EEG localization in peripheral nerve patients, High-density EEG localization in stroke patients
Epilepsy Clinical Trial 2023: High-density electroencephalogram (HD-EEG) Highlights & Side Effects. Trial Name: NCT04266041 — N/A
High-density electroencephalogram (HD-EEG) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04266041 — N/A
~32 spots leftby Feb 2028